Shanghai Fosun Pharmaceutical said it will work with German partner BioNTech to develop a new vaccine targeting the omicron variant of COVID-19, but it may take three to four months to win regulatory approval.
Fosun is the exclusive partner of BioNTech for marketing the mRNA vaccine co-developed by BioNTech and U.S. drug giant Pfizer in greater China, which includes Hong Kong, Macao and Taiwan. Known in China as the Comirnaty vaccine, the product has not been approved for the Chinese mainland.
